From the Amazon, Berkshire Hathaway, and JPMorgan Chase venture to the CVS-Aetna deal, a number of corporate behemoths have recently announced mergers that, they say, are sure to shake up health care. But while these superpower alliances are making a splash in the headlines, will they actually be able to disrupt, and save, U.S. health care? Will consumer focused models and employer-led initiatives lead to better and less expensive outcomes?

Debating in support of the motion are Collective Health co-founder Dr. Rajaie Batniji and Ernst & Young LLP (EY) partner and Global Health Transactions Advisory Services Leader Gregg Slager. Debating against the motion are Gist Healthcare co-founder Dr. Lisa Bielamowicz and Day Health Strategies founder Rosemarie Day.

The debate will be stream live online from the Mayo Clinic's Transform Conference in Rochester, Minn., then air soon after as part of the syndicated public radio show and podcast "Intelligence Squared U.S." On September 26, online viewers can tune in at IQ2US's website: https://www.intelligencesquaredus.org/debates/retail-alliances---not-washington---will-save-us-health-care-system

WHAT: Intelligence Squared U.S. Debates "Retail Alliances - Not Washington - Will Save the U.S. Health Care System"
WHEN: Wednesday, September 26, 2018 / 6:00-7:30 PM ET
WHERE: Mayo Clinic Transform Conference / Mayo Civic Center, 30 Civic Center Dr. SE, Rochester, Minn.
STREAM LIVE: http://www.intelligencesquaredus.org/

Arguing for the motion:

* Dr. Rajaie Batniji: Co-Founder & Chief Health Officer, Collective Health
Dr. Rajaie Batniji is a physician, political economist, and the co-founder of, and chief health officer at, Collective Health, an organization that leads the employer-driven health care economy and aims to create a more efficient health care experience. In his position, he oversees partnerships with health care networks and health care providers, analytics teams, and Collective Health's employee health management programs. Dr. Batniji is also a clinical assistant professor of medicine at the Stanford University School of Medicine.

* Gregg Slager: Partner & Global Health Transactions Advisory Services Leader, Ernst & Young LLP
Gregg Slager is senior partner and Global Health Transactions Advisory Services Leader at EY, a leader in providing assurance, tax, transaction and consulting services. With more than 30 years of experience in healthcare and a founding member of EY's healthcare practice, Gregg works with organizations across sectors to help them interpret, reimagine, and thrive in the health ecosystem of the future by providing innovative, data driven solutions that help inform care delivery. Slager frequently speaks and writes about healthcare mergers and acquisitions and has a passion for working with organizations across sectors to manage health costs, improve efficiency and facilitate better health outcomes.

Arguing against the motion:

* Dr. Lisa Bielamowicz: Co-Founder & President, Gist Healthcare
Dr. Lisa Bielamowicz is the co-founder and president of Gist Healthcare. Her work combines national-level insight with a deep understanding of local market dynamics and system strength. Prior to founding Gist, Dr. Bielamowicz was the chief medical officer and senior vice president of the Advisory Board Company, where she led the firm's strategy and clinical research for over a decade. As a physician, Dr. Bielamowicz brings a clinical lens to her work and has a deep understanding of the dynamics of physician practice.

* Rosemarie Day: Founder & CEO, Day Health Strategies
Rosemarie Day is founder and CEO of Day Health Strategies. She has over 25 years of experience in the public, private, and non-profit sectors, including 16 years of leadership experience in state government. Day served as the founding deputy director and chief operating officer of the Health Connector in Massachusetts, where she played a significant role in launching the first state-run health insurance exchange in the United States. She also served as the chief operating officer for the Massachusetts Medicaid program, covering more than one million members.

ABOUT INTELLIGENCE SQUARED U.S.

A non-partisan, non-profit organization, Intelligence Squared U.S. was founded in 2006 to address a fundamental problem in America: the extreme polarization of our nation and our politics. Their mission is to restore critical thinking, facts, reason, and civility to American public discourse. The award-winning debate series reaches over 30 million American households through multi-platform distribution, including radio, television, live streaming, podcasts, interactive digital content, and on-demand apps on Roku and Apple TV. With over 150 debates and counting, Intelligence Squared U.S. has encouraged the public to "think twice" on a wide range of provocative topics. Author and ABC News correspondent John Donvan has moderated IQ2US since 2008.

ABOUT THE MAYO CLINIC CENTER FOR INNOVATION AND TRANSFORM

The Mayo Clinic Center for Innovation (CFI) taps the resources, ingenuity, and legacy of Mayo Clinic's 150+ years of medical leadership. The center offers a unique space within Mayo Clinic to rapidly iterate new ideas into the practice. CFI's multidisciplinary team uses a human-centered design approach to turn innovative ideas into practical solutions that change how people can determine their own health and experience the delivery of health and health care.

Since 2008, Transform has been the annual health care innovation conference that connects decision makers, change agents, and stakeholders from around the world. It is a platform to challenge assumptions, collaborate, and share results that accelerate health innovation by focusing on people at the center of an emerging ecosystem for health. Currently, the Center for Innovation is being integrated into the expanded and highly capable Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery to ensure maximum alignment with the needs and strategic direction of Mayo Clinic.

Go here for photos, links and more info: http://shorefire.com/client/intelligence-squared-us

Experts Call for Improved Identification of 'High Burden' Rosacea Patients in Everyday Practice

Loss Is A Four-Letter Word
A Bereavement Boot Camp for the Widowed

By Carole Brody Fleet

"Carole Brody Fleet is forthright in dealing with many of the difficult issues surrounding widowhood, demonstrating that you do not have to live in your past. It's not an either-or situation. She teaches the important lesson that you can incorporate your previous life into a new life.”
—Jane Brody, personal health columnist, The New York Times

Deerfield Beach, FL, September 13, 2018 — No widow or widower look exactly the same. No widowhood looks exactly the same. Therefore, no healing journey or timeline is an identical experience. The word "loss” contains only four letters, but its size belies the amount of fear it produces at even its mere mention. Even more terrifying and enormous is the reality of loss–specifically, the loss of a spouse.

Widowhood has the capacity to keep those affected from moving forward into a new and fulfilling life. The loss of a spouse is frightening. The call for relatable and actionable direction and advice remains a very real need for the widowed community, and that is just what Loss is a Four-Letter Word offers. Award-winning author Carole Brody Fleet personally experienced the pain and grief as a young widow and mother; leaving her and her 9-year-old daughter alone. Loss is a Four-Letter Word shows readers a way out, a way to move forward– not "get over”–their most profound loss in positive ways. Fleet combines no-nonsense, direct advice with specific, boot-camp style "assignments” that are framed with compassion and humor to help them through a most challenging life-journey.

A short sample of the Bereavement Boot Camp Lessons:

•    Lesson One: I'm Still Here
•    Lesson Two: "My Healing Journey Is Mine”
•    Lesson Three: Stop Putting Off Proactivity
•    Lesson Four: "I Turn to… Who?”
•    Lesson Five: Put Your Tits on Your Back
•    Lesson Six: Get Up, Get Moving… Get Out!
•    Lesson Seven: It's Your Turn
•    Lesson Eight: Past, Present, and Future: You Can Have All Three

Loss is a Four-Letter Word gives readers help without reproach, education without lecture, and support without judgment, condition, or negative opinion. All of which provides a necessary light during such devastating times. Fleet tells them, "Because while our spouses may have departed this earth, we are still here. And we matter too.”

About the Author:

Carole Brody Fleet is the award-winning author of When Bad Things Happen to Good Women, Happily EVEN After, and Widows Wear Stilettos. Widely recognized as America's go-to expert on life adversity and grief recovery, Ms. Fleet is also a three-time contributor to the iconic Chicken Soup for the Soul book series, as well as a regular contributor to The Huffington Post and to ThirdAge.com. Ms. Fleet is also a popular motivational speaker and with her inimitable message of "What Now and What Next?” Ms. Fleet offers practical, emotional, and even humorous guidance to the millions who have experienced any kind of loss or challenge in their lives.

Loss Is A Four-Letter Word: A Bereavement Boot Camp for the Widowed
By Carole Brody Fleet
ISBN: 9780757321214
September 2018
$15.95
Available wherever books are sold or to order directly from the publisher, contact:
(800) 441-5569 or www.hcibooks.com

Reviews:

Karen Noé, author, We Consciousness: 33 Profound Truths for Inner and Outer Peace and Your Life After Their Death: A Medium's Guide to Healing After a Loss: "Carole Brody Fleet has done it again! In Loss is a Four Letter Word, she offers practical, straightforward advice on how to move forward on a positive path after losing a loved one. I've had Carole as a guest on the "Angel Quest” radio show a number of times because of how much she has benefited my listeners with her knowledge. If it sounds like I am impressed with her, it's because I am. I love this book, and I love Carole!”

Lisa Lockwood, crime analyst, author, police and military veteran: "What I love and appreciate is Carole Brody Fleet's firsthand knowledge and approach on the most taboo topic in society. Having gone through personal loss, I always learn something about how to approach the topic with empathy and how to permit others to comfort me in the worst of times.”

Stacey Gualandi, Emmy award-winning journalist: "Carole Brody Fleet has faced painful challenges and loss with courage and resilience. Through her own personal healing, we can all learn from and be inspired by her.  I have a four-letter word for Carole: HERO.”

Kristin Higson-Hughes, Senior Features Editor, Women's World Magazine: "Just as there is no timetable to grief, there certainly is no checklist on how to recover strength and joy after suffering a loss. Here you will find authentic, candid, trustworthy, and--perhaps most pertinent of all--pragmatic advice promising that although the landscape of life may forever be changed, the future can still hold purpose, beauty, and magic. With a signature style all her own, Carole Brody Fleet "trains" you to find yourself again (hint: there's no wrong path, but some are healthier for your soul!). Together, you will navigate everything from social media to financial matters to the possibility of finding love again. Sure, it can feel impossible to do, and even more so to find answers, but sign up, dear recruit, and discover this book's wit and wisdom, and its author's enormous-as-the-universe heart!"

Kim Iversen, nationally syndicated radio show host: "Carole is an angel, not just an expert. Many of us have no clue what to say to a loved one going through tremendous loss. We sit by and watch helplessly as they struggle with their 'new normal'. Carole's book is a must read; not just for widows, but for those of us who love a widow as well. As a relationship radio talk show host, I have always had words to comfort and guide someone through every type of heartache-----every heartache except the death of a spouse. This type of loss leaves many of us speechless. Finally, someone who knows what to say when the rest of us do not."

Powerful Story Shares One Woman's Struggle To Overcome Abandonment And Abuse

Raleigh, NC, Sept. 13, 2018 ― Deja' was dealt a losing hand, and no one would have blamed her for simply accepting her fate. Her father died before she was born, and her mother chose drug addiction over her daughter. With loneliness consuming her, Deja' could have folded. Should have folded. But instead, she learned how to recycle her pain, and she began drawing from every source of positive influence that entered her life: a God-loving grandmother, a supportive godmother and a street-savvy godfather who taught her how to redirect her pain and survive in this world.

But the challenges just kept coming, and Deja' encountered countless betrayals and abuses along the way, which lead to an unhealthy marriage, and ultimately, a pattern of unhealthy relationships with men that lasted for several years. Aware that she is repeating a family cycle of poor choices, Deja' needs to rally what's left of her strength and determination to break that cycle. Will her fortitude be enough? Or will this final test break her spirit once and for all?

Overcoming the Hand You Were Dealt is the powerful new book from Kisha Taylor. Cultivated from her personal experience with abandonment, Overcoming weaves an authentic and captivating story of struggle, pain, hope and faith that culminates in a heartwarming climax of healing and restoration.

In addition to the book, Taylor's website, lifeunlimited1.com, enables her to continue her passion for women's emotional health, with courses that tap into the warrior in every woman, that cover abandonment issues and that help survivors understand why they act and feel the way they do. The website also houses inspirational items like T-shirts and mugs with messages of empowerment, and a blog with videos and messages of encouragement.

Author Kisha Taylor was born in Brooklyn, NY, and from a young age, she learned how to navigate the real world of hard knocks. She attended Binghamton University and Baruch College, where she studied accounting and psychology. She became counsel to many, sharing principles on surviving abuse, overcoming life's challenges, healthy ways of handling personal mistakes and how to not surrender to self-defeat.

She is most proud of the lives her journey has impacted, as well as the happiness, confidence and emotional health she now has, which enables her to be a testament of, "You can, if you just don't give up.”

To read more from Taylor, or to view her motivational videos, please visit www.lifeunlimited1.com.

Overcoming the Hand You Were Dealt
Pendium publishing
Release date: February 5, 2018
ISBN-10: 1944348409
ISBN-13: 978-1944348403
Available at www.lifeunlimited1.com, Amazon.com, and all other online outlets.

Possible Questions for Kisha Taylor:

How did I forgive my mom for her drug addiction and abandonment?

How did I move past abandonment, molestation and adultery to become a bank VP, own several investment properties, and write a book?

After being molested and spending years fearing men—along with being betrayed by men I cared about—do I believe I can ever trust a man again?

What is one of the greatest threats to success and emotional health for a woman who has experienced betrayal, abuse and abandonment?

What am I most proud of in my life?

If I could do anything differently what would it be?

Excerpts from Reviews:

"… Every woman can relate to the situations in this book.”

"… Anyone that reads it would benefit from it. … It's definitely a self-help book.”

Approval of Keytruda in Europe for first-line use with chemotherapy in lung cancer strengthens the use of PD-1 inhibitors as backbone therapy, says GlobalData

Following FDA approval in August, this week (wk comm 10^th Sept) the European Commission (EC) also approved Merck Sharp & Dohme (MSD)'s PD-1 blocking antibody, Keytruda (pembrolizumab), for use as a first-line therapy in combination with Eli Lilly’s Alimta (pemetrexed) plus platinum chemotherapy, for patients with metastatic non-small cell lung cancer (NSCLC) who have no EGFR or ALK positive mutations.

Keytruda is a recombinant monoclonal antibody that is already approved for a number of cancer types in Europe, including metastatic melanoma, classical Hodgkin lymphoma, urothelial carcinoma, and as a single agent for the treatment of patients with metastatic NSCLC whose tumors have high PD-1 ligand (PD-1L) expression. Keytruda acts by blocking the interaction of PD-1 with its ligand (PD-L1), releasing PD-1 pathway-mediated inhibition of the immune response and thereby activating T-cell immune surveillance of tumor cells.

According to GlobalData’s report, 'PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities' , among the checkpoint modulators, antibodies targeting PD-1 and PD-L1 [PD-(L)1] account for more than half of clinical trials and have experienced exponential growth since 2015.

GlobalData expects that this trend will continue in the coming year as PD-(L)1 inhibitors are being explored in new cancers, such as pancreatic cancer, hepatocellular carcinoma, and acute myeloid leukemia. Furthermore, marketed PD-(L)1 inhibitors are moving into earlier lines of treatment and are increasingly explored in combination trials utilizing PD-(L)1 as a backbone therapy for existing or innovative therapeutic strategies.

Dr Edit Kovalcsik, Managing Analyst at GlobalData, commented, “Lung cancer is one of the most common cancers and NSCLC makes up approximately 85% of all lung cancers. Therefore NSCLC covers the most lucrative field in the lung cancer space.”

GlobalData’s report, ‘Non-Small Cell Lung Cancer (NSCLC) - Dynamic Market Forecast to 2025’, reveals that approximately 177 thousand cases were diagnosed with NSCLC in 2017 in the five European markets – France, Germany, Italy, Spain and the UK. The report also forecasts that Merck’s Keytruda will become the lead therapy in NSCLC with forecasted global sales across the 8MM (US, 5EU, Japan and China) of USD $3bn by 2025.

IMAGE FOR PUBLICATION: Please click here for chart: Forecasted 8MM Sales of Top Immunotherapy Drugs in NSCLC, 2015-2025

The EC’s decision of approval of Keytruda-chemo cocktail was based on the KEYNOTE-189 trial, in which the combination therapy reduced the risk of death by half, compared with Alimta and chemotherapy (cisplatin or carboplatin) alone. In addition, the Keytruda combination significantly improved the progression-free survival (PFS) compared with Alimta and chemotherapy alone.

Roche’s Tecentriq and Bristol-Myers Squibb’s Opdivo are direct competitors to Keytruda. Keytruda’s approval in the first line setting combined with chemotherapy comes as a blow for Roche as last week the FDA delayed its decision on the use of Tecentriq in combination with Avastin and chemotherapy in the frontline setting for metastatic NSCLC by three months. BMS’ Opdivo plus Yervoy combination could also challenge Merck’s Keytruda combination in the frontline NSCLC, as the FDA accepted BMS’ application in June 2018 to market the immuno-oncology combination, based on the improved PFS demonstrated in the CheckMate-227 trial.

Kovalcsik concluded, ‘‘Approval of Keytruda-chemo combination therapy paves the way for the frontline use of PD-(L)1 combination therapies in the NSCLC space.”

GlobalData.com | LinkedIn | Twitter

About GlobalData

4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors. PR2744

With Alzheimer’s treatment stalled, promising pipeline drugs and a shift in perception could be key to tackling the disease, says GlobalData

As World Alzheimer’s Day approaches (21 September) with the aim of raising global awareness and understanding of the issues faced by people affected by dementia it’s timely to reflect that no new drug for Alzheimer’s disease (AD) has been approved in the past 16 years, despite more than 400 clinical trials and billions of dollars being spent in an attempt to tackle the disease and address unmet needs, says GlobalData a leading data and analytics company.

According to GlobalData’s latest report, ‘Alzheimer’s Disease: Competitive Landscape to 2026’, the pipeline has been characterized by big failures, as AD drug development is considered to have one of the highest failure rates of all indications. The AD pipeline features 657 drugs across all stages of development, and out of these, only 3.2% of drugs are in late stage development; which is dominated by small molecules and monoclonal antibodies. The report reveals that Amyloid precursor protein (Aβ peptide and protein) and microtubule associated protein tau (MAPT) are the major targets being pursued by companies developing drugs against AD.

Alessio Brunello, Pharma Analyst at GlobalData, commented, ‘‘The need for new disease modifying drugs (DMDs) is urgent as the current competitive landscape in AD offers medications that are aimed at treating only the symptoms of the disease. A few key drugmakers have already stopped their research into AD, and given the significant amount of R&D failures, pharma companies may be disincentivized from producing new drugs. The amyloid hypothesis has been the central theory for the pathogenesis of AD, but all Aβ-targeting drugs treating AD have ended in failure. In fact, recent studies indicated that one of the main factors concerning the development and progression of the disease could be tau and not beta amyloid. We may, in the future, see tailored therapies to include potentially both an anti-amyloid and an anti-tau approach being administered concurrently.”

Currently, treatments for AD consist only of symptomatic treatments, of which there are only five approved medications: three cholinesterase inhibitors (ChEIs) (donepezil, rivastigmine, and galantamine), one N-methyl-D-aspartate receptor (NMDA-R) antagonist (memantine), and one combination therapy (memantine/donepezil). These leave a lot to be desired in terms of efficacy, routes of administration, and dosing frequencies.

The potential launch of promising monoclonal antibodies from Biogen (aducanumab) and Roche (gantenerumab and crenezumab) will boost the size of the Alzheimer’s market given their potential to halt or prevent disease progression. Most of the tau-targeting approaches that are currently in clinical trials are immunotherapies such as Axon neuroscience’s AADvac-1 and Eli Lilly’s LY3303560. Tau is more likely to be a better target than Aβ as the clinical stages of cognitive decline much better correlate with the number, density and distribution of tangles than does the Aβ burden.

Brunello concludes, ‘‘Monoclonal antibodies have shown more promise than anything in the pipeline and in the next 10 years, we're going to have a good idea on whether amyloid is really a meaningful player or not. The industry shifted a little to anti-tau therapies, showing that tau treatments represent a new direction with a possible combination approach if trials will provide positive results. In the absence of any proven disease-modifying therapy, if and when one will reach the market, the rewards in term of profits for the developer would be huge.”

About GlobalData
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors. PR2669

WHY GOING COLD TURKEY FROM ALCOHOL CAN KILL YOU

www.beachway.com

One out of every 12 adults in the United States suffers from alcohol dependence, making alcohol the most regularly used addictive substance in America, the National Council on Alcoholism and Drug Dependence (NCADD) reports. Drinking large amounts of alcohol regularly can cause the brain to get used to the way that alcohol interferes with neurotransmitter transmission, movement, and absorption. If you’re a heavy drinker, abruptly quitting alcohol without the help of medical professionals — known as going “cold turkey” — can be painful and dangerous. Carrie Carlton, Clinical Director (LCSW)  of Beachway Therapy Center in Boynton Beach, Florida gives the lowdown on what you should know if you’re considering detoxing from alcohol on your own and why you might want to consider an in-patient medical detox.

According to Carrie Carlton LCSW, “When someone who has become "alcohol dependent" decides to stop drinking, he/she will experience some level of physical discomfort. For this reason, it is extremely difficult for a person to merely stop drinking "on their own" without assistance and support.”

What are the Dangers and Symptoms When Someone Stops Cold Turkey

Common symptoms include:

Depression

Anxiety

Headache

Fatigue

Nausea and vomiting

Nightmares

Shakiness

Fever

Irritability

Delirium Tremens

Getting the Shakes

For those who are less chemically dependent, withdrawal symptoms might be as "mild" as merely getting the shakes, or the sweats—or perhaps nausea, headache, anxiety, a rapid heartbeat, and increased blood pressure. Although these symptoms are uncomfortable and irritating, they are not necessarily dangerous. But they are often accompanied by "craving" more alcohol, making the decision to continue abstinence much more difficult to make. Even the "morning after" hangover of someone who only occasionally drinks to excess is actually a mild form of alcohol withdrawal from the excesses of the night before, as the alcohol content of their blood begins to drop. The symptoms can appear within a few hours after not drinking.

The Full-Blown DTs

Within six to 48 hours after not drinking, hallucinations may develop. These usually are visual hallucinations but they can also involve sounds and smells. They can last for a few hours up to weeks at a time. Also, within this time frame after quitting, convulsions or seizures can occur, which is the point at which alcohol withdrawal can become dangerous if not medically treated. The symptoms may progress to delirium tremens (DTs) after three to five days without alcohol. The symptoms of DTs include profound confusion, disorientation, hallucinations, hyperactivity, and extreme cardiovascular disturbances. Once DTs begin, they can cause cardiac disturbances, seizures and other medical complications that can be fatal.

Alcohol Withdrawal Timeline

First 12 hours     Heavy drinkers experience tremors a few hours after their last drink. Symptoms during the first 12 hours include sweating, irritability, rapid heartbeat, high blood pressure, nausea, vomiting and insomnia.

Days 1-2    Symptoms peak 24 to 48 hours after the last drink. Symptoms are most severe and may include seizures, night terrors, hallucinations and panic attacks.

Days 3-5    Ongoing feelings of nervousness, shakiness and mood swings can last up to a week after the last drink. Delirium tremens may occur during this time as well.

Days 6+      After detox, some former heavy drinkers experience longer-lasting effects of withdrawal. Symptoms are mostly psychological. They may include mood swings, anxiety, irritability, changing levels of energy and trouble sleeping. These symptoms come in waves and can last for months after the last drink.

What can a medical detox do that going it alone cannot achieve?

Medications Used During Alcohol Detox

When alcohol detox is treated in an inpatient rehab facility, different medications may be used to help reduce uncomfortable withdrawal symptoms. Medications can also help keep a person’s body chemicals in balance, lowering the risk for serious complications. In rehab, a medical professional will administer the medication and monitor its effects. If the medication begins to cause unwanted side effects or interferes with the detox process, another remedy can be used. Typically, vital signs are checked every few hours as well as body temperature.  Patients are often given anti-seizure medication and benzodiazepines such as valium to make the withdrawal more physically tolerable.  An in-house detox also makes things psychologically easier for the patient, as they are around other clients who are going through the same experience.

Several medications commonly administered during the detox phase are:

Benzodiazepines

Benzodiazepines (benzos) are most frequently used to treat withdrawal symptoms during the alcohol detox phase. They are used to help calm your central nervous system and may also be prescribed to treat insomnia, anxiety and muscle spasms.

Naltrexone

Naltrexone helps reduce alcohol cravings during the detox stage. In the event of a relapse, naltrexone works by inhibiting the high feeling that alcohol may cause. Since the medication can stimulate withdrawal symptoms, it is recommended that you wait seven to 10 days before taking naltrexone.

Acamprosate

Years of heavy drinking can significantly alter how the brain looks and works. Acamprosate, sold under the name Campral, is prescribed to help your brain begin to function normally again after you quit drinking. Research studies have also started to look into whether or not acamprosate helps reduce the symptoms of PAWS including insomnia, anxiety and restlessness. It also works to reduce alcohol cravings; however, it will not produce an unwanted effect if alcohol is consumed.

Disulfiram

Another medication used in the treatment of alcoholism is disulfiram. Unlike other medications, disulfiram works by producing severe reactions if alcohol is consumed. For instance, if you drink while on disulfiram, you will experience unwanted effects like facial flushing, nausea, headache, weakness and low blood pressure. The negative effects are meant to deter you from continuing your drinking pattern. Disulfiram is not meant to reduce your alcohol cravings or restore brain functions like some other medications.

What should patients do after treatment at a detox facility?

Beachway Therapy provides detox treatment and also residential treatment programs at another site, that entails a minimum stay of 30 days and can be more.  Once the physical detox is over, it is here that patients learn the long term tools to stay sober.  In addition, a continuing outpatient plan of care is established for each patient prior to leaving treatment.

About Beachway Therapy Center

At Beachway we understand that there may not be a second chance at recovery so we strive to be the last treatment program you will need.  By providing a continuum of care, from PHP (Partial Hospitalization Program) to Outpatient services, we can offer a fully individualized treatment plan that meets the clinical and medical needs of each client. Length of stay will vary for each client, most of our clients stay between 30 and 90 days, determined on an individualized basis.  By providing an extremely low client to therapist ratio we can identify and address underlying, co-occuring disorders.  Under such professional supervision clients can begin to recover in a safe, residential-like environment.  Some of the Therapeutic Methods that we use at Beachway are:

Our multidisciplinary team of credentialed and veteran staff utilize the latest evidence-based practices in medical, psychiatric and addiction treatment, including CBT (cognitive behavioral therapy) motivational interviewing, addiction counseling, 12-Step orientation, DBT (dialectical behavioral therapy,) trauma informed practices and a wide variety of supportive group therapies.

Carrie Carlton, Clinical Director (LCSW)

Carrie is the Clinical Supervisor at Beachway and holds a BSW and MSW in social work from Florida Atlantic University, a MA from Barry University (Miami), and is a Licensed Clinical Social Worker. She also has a background in medical social work. Her understanding of cognitive behavioral therapy, solution focused therapy, and family systems guides her treatment of addicts and families. Her clients thrive under her guidance because of her honesty, empathy, and compassion. Recognizing the severe impact of addictions on both the addict and the families, Carrie is dedicated to consistently

Canadian public engagement platform Carrot Rewards ranks Top 20 on the Canadian Business and Maclean's 2018 Startup 50

Innomane Inc. Announces Health Canada Approval and Canadian Launch of Diaronex®, an Over-The-Counter Herbal Remedy to Help Relieve Diarrhea

Gripping Memoir Details Life Before And After Debilitating Stroke

Trevose, PA, September 12, 2018 ― For Mary Reid-Hill, the word "no” means surrender. It means life on the couch. It means dying a slow death. So never tell Mary that she can't do something. Because she'll do everything in her power to prove you wrong.

Mary entered "adulthood” with a load of problems to unpack, including a twisted, abusive childhood; a misguided teen marriage; and a cancer diagnosis at the tender age of 22. Somehow, in spite of it all, she used her skills as a visual artist to carve out a career in the male-dominated world of sign design and installation.

But life wasn't done testing her. At age 38, at the peak of her success, she suffered a major stroke which left her with essentially half her brain and body capacity. For more than 15 years, she has defied doctors, therapists, and even friends and family to stubbornly and relentlessly find her own equilibrium and happiness, "in spite of” all of her health challenges, psychological roadblocks and spiritual upheaval.

But that's just Mary.

And now, she's sharing her remarkable story in her inspirational memoir, In Spite Of . . . How I Survived Abuse, Cancer, and a Giant F@#%ing Stroke, as told to David Tabatsky—author, co-author and/or editor of more than thirty books, covering a vast range of subjects. For more information on David, please visit his website at: www.tabatsky.com.

Mary's approach is refreshingly candid and infused with humor as she chronicles a series of life events that would emotionally cripple most people, including her messed- up childhood, two bad marriages, the devastating stroke, her battles with weight and insurance companies, and the death of her husband. Through it all, her no-nonsense prose underscores why she's become a living example of what the human spirit is ultimately all about and how, in spite of it all, she's still here.

Mary was born and raised in Bucks County, Pennsylvania, and still lives there today, on the corner of Hope and Humor. For the past 17 years, Mary has been unable to hold down a job, due to a disability stemming from her stroke. However, she remains as active as possible, renovating her home, refinishing furniture and continuing her main passion––drawing. Her memoir includes 15 original drawings, some of which she created before the stroke, and several after, when she had to teach herself to draw all over again, this time with her left hand. On top of that, Mary cares for two dogs and occasionally her two closest sisters.

For more information, please visit the website at: www.inspiteof.life.

In Spite Of . . . How I Survived Abuse, Cancer, and a Giant F@#%ing Stroke
Legacy Projects
Release Date: August 2018
ISBN–13: 978-1722983352
ISBN–10: 1722983353